Cabenuva, a co-packaged antiretroviral treatment designed specifically for people living with HIV, represents far more than just two vials containing cabotegravir and rilpivirine — it represents a breakthrough in how we talk about adherence, empowerment, and long-term viral suppression. Being part of the team that helped bring its digital presence to life was both a technical undertaking and a deeply personal one for me as a queer creative who has watched the evolution of HIV treatment reshape our community’s history.

None of the work would have been possible without strong leadership and the highly disciplined studio production team steering the ship. As a digital artist, I had the privilege of collaborating closely with incredibly skilled partners across Havas and its affiliated agencies, Arnold and Tonic. These teams routinely navigate the complex world of pharmaceutical regulations and accelerated timelines, and together we were able to align strategy, science, and storytelling into a seamless digital ecosystem.

By the time Cabenuva reached the point where it could begin final design and development for its online platform, the brand had cleared a significant number of regulatory hurdles. The story it needed to tell was both medically precise and emotionally grounded — speaking to HIV-positive patients looking for lower viral loads, greater treatment flexibility, and the promise of a long-acting regimen that could materially improve quality of life. Translating those truths into a digital experience required nuance, restraint, and clarity.

The build began as a series of extensive Photoshop files — dense with layers, nested modules, and multiple branching pathways within the broader site map. My task was to migrate this ecosystem into Sketch to create lightweight, vector-based assets that would not only accelerate development but also allow for real-time collaboration with UX, copy, brand, and medical-legal partners. Streamlining a site of this complexity is its own art form; every component had to be optimized to support both desktop and mobile-responsive layouts while remaining compliant with FDA guidance, accessibility standards, and the needs of multiple stakeholders.

Because the project is still protected under NDA, I’m not able to share the working files or live build. But the process itself — navigating regulatory guardrails, structuring clear user journeys, and ensuring the visual language honored both the science and the lived experiences of the HIV community — was one of the more meaningful digital pharma engagements of my career. It reaffirmed my belief that design is at its strongest when it bridges humanity and innovation, and when the work has the potential to support real people in real ways.